|4May 22, 4:30 PM ET

Caissa Capital Management ltd. 4

4 · Avalo Therapeutics, Inc. · Filed May 22, 2023

Insider Transaction Report

Form 4
Period: 2023-05-18
Transactions
  • Purchase

    Common stock

    2023-05-18$3.29/sh+13,121$43,1631,360,200 total(indirect: See Footnote (1))
  • Purchase

    Common stock

    2023-05-22$3.34/sh+7,000$23,3581,373,700 total(indirect: See Footnote (1))
  • Purchase

    Common stock

    2023-05-19$3.52/sh+6,500$22,8521,366,700 total(indirect: See Footnote (1))
Holdings
  • Common stock

    182,300
Footnotes (5)
  • [F1]Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.80 to $3.40, inclusive.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4 to $3.6, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.72, inclusive.
  • [F5]These share are directly owned by Mr. Golestaneh in his personal capacity.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT